171 related articles for article (PubMed ID: 38674197)
1. Treatment of Osteoporosis in Men on Androgen Deprivation Therapy in Japan.
Nishimoto H; Inui A; Mifune Y; Yamaura K; Bando Y; Okamura Y; Hara T; Terakawa T; Kuroda R
Medicina (Kaunas); 2024 Mar; 60(4):. PubMed ID: 38674197
[No Abstract] [Full Text] [Related]
2. Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.
Alibhai SM; Mohamedali HZ; Gulamhusein H; Panju AH; Breunis H; Timilshina N; Fleshner N; Krahn MD; Naglie G; Tannock IF; Tomlinson G; Warde P; Duff Canning S; Cheung AM
Osteoporos Int; 2013 Oct; 24(10):2571-9. PubMed ID: 23563932
[TBL] [Abstract][Full Text] [Related]
3. Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis.
Joseph JS; Lam V; Patel MI
Eur Urol Oncol; 2019 Sep; 2(5):551-561. PubMed ID: 31411986
[TBL] [Abstract][Full Text] [Related]
4. A randomized, open-label, controlled trial of monthly oral minodronate or semiannual subcutaneous injection of denosumab for bone loss by androgen deprivation in Asian men with prostate cancer: the PRevention of Osteopenia with Minodronate And DEnosumab (PROMADE) study.
Yoshida T; Kinoshita H; Taniguchi H; Yanishi M; Sugi M; Matsuda T
Osteoporos Int; 2020 Jul; 31(7):1251-1259. PubMed ID: 31993719
[TBL] [Abstract][Full Text] [Related]
5. Management of decreased bone mineral density in men starting androgen-deprivation therapy for prostate cancer.
Panju AH; Breunis H; Cheung AM; Leach M; Fleshner N; Warde P; Duff-Canning S; Krahn M; Naglie G; Tannock I; Tomlinson G; Alibhai SM
BJU Int; 2009 Mar; 103(6):753-7. PubMed ID: 19007370
[TBL] [Abstract][Full Text] [Related]
6. A randomized phase II trial evaluating different schedules of zoledronic acid on bone mineral density in patients with prostate cancer beginning androgen deprivation therapy.
Lang JM; Wallace M; Becker JT; Eickhoff JC; Buehring B; Binkley N; Staab MJ; Wilding G; Liu G; Malkovsky M; McNeel DG
Clin Genitourin Cancer; 2013 Dec; 11(4):407-15. PubMed ID: 23835291
[TBL] [Abstract][Full Text] [Related]
7. Denosumab in men receiving androgen-deprivation therapy for prostate cancer.
Smith MR; Egerdie B; Hernández Toriz N; Feldman R; Tammela TL; Saad F; Heracek J; Szwedowski M; Ke C; Kupic A; Leder BZ; Goessl C;
N Engl J Med; 2009 Aug; 361(8):745-55. PubMed ID: 19671656
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.
Miyazawa Y; Sekine Y; Syuto T; Nomura M; Koike H; Matsui H; Shibata Y; Ito K; Suzuki K
Anticancer Res; 2017 Jul; 37(7):3667-3671. PubMed ID: 28668858
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density, pathological fractures and bisphosphonate therapy in prostate cancer patients on androgen deprivation therapy.
Ziaran S; Goncalves FM; Breza JS
Endocr Regul; 2011 Oct; 45(4):199-204. PubMed ID: 22073949
[TBL] [Abstract][Full Text] [Related]
10. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
Ryan CW; Huo D; Stallings JW; Davis RL; Beer TM; McWhorter LT
Urology; 2007 Jul; 70(1):122-6. PubMed ID: 17656221
[TBL] [Abstract][Full Text] [Related]
11. Bone Health and Bone-Targeted Therapies for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis.
Alibhai SMH; Zukotynski K; Walker-Dilks C; Emmenegger U; Finelli A; Morgan SC; Hotte SJ; Tomlinson GA; Winquist E
Ann Intern Med; 2017 Sep; 167(5):341-350. PubMed ID: 28785760
[TBL] [Abstract][Full Text] [Related]
12. Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.
Kiratli BJ; Srinivas S; Perkash I; Terris MK
Urology; 2001 Jan; 57(1):127-32. PubMed ID: 11164157
[TBL] [Abstract][Full Text] [Related]
13. Responder analysis of the effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
Egerdie RB; Saad F; Smith MR; Tammela TL; Heracek J; Sieber P; Ke C; Leder B; Dansey R; Goessl C
Prostate Cancer Prostatic Dis; 2012 Sep; 15(3):308-12. PubMed ID: 22641239
[TBL] [Abstract][Full Text] [Related]
14. Preventing bone loss during androgen deprivation therapy for prostate cancer: early experience with neridronate.
Magno C; Anastasi G; Morabito N; Gaudio A; Maisano D; Franchina F; Galì A; Frisina N; Melloni D
Eur Urol; 2005 May; 47(5):575-80; discussion 580-1. PubMed ID: 15826746
[TBL] [Abstract][Full Text] [Related]
15. Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.
Kato S; Kawase M; Kato D; Ishida T; Uno M; Fujimoto Y; Masue T; Masue N; Deguchi T
J Bone Miner Metab; 2019 Jan; 37(1):72-80. PubMed ID: 29313098
[TBL] [Abstract][Full Text] [Related]
16. Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.
Planas J; Trilla E; Raventós C; Cecchini L; Orsola A; Salvador C; Placer J; Encabo G; Morote J
BJU Int; 2009 Dec; 104(11):1637-40. PubMed ID: 19549260
[TBL] [Abstract][Full Text] [Related]
17. Treatment thresholds for osteoporosis in men on androgen deprivation therapy: T-score versus FRAX.
Adler RA; Hastings FW; Petkov VI
Osteoporos Int; 2010 Apr; 21(4):647-53. PubMed ID: 19533207
[TBL] [Abstract][Full Text] [Related]
18. [Osteoporosis in men receiving androgen deprivation therapy for non-metastatic prostate cancer].
Kudlacek S; Puntus T
Wien Med Wochenschr; 2012 Sep; 162(17-18):380-5. PubMed ID: 22875632
[TBL] [Abstract][Full Text] [Related]
19. Management of osteoporosis in men on androgen deprivation therapy.
Adler RA
Maturitas; 2011 Feb; 68(2):143-7. PubMed ID: 21129866
[TBL] [Abstract][Full Text] [Related]
20. Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.
Wu C; Chen W; Huang X; Lin R; Wu J; Zhang X
Clin Genitourin Cancer; 2018 Dec; 16(6):e1243-e1250. PubMed ID: 30146230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
